目的：分析鉴定口服生脉散后大鼠血中移行成分，揭示生脉散的药效物质基础。方法：应用UPLC-HDMS 技术建立生脉散以及大鼠口服生脉散后含药血清样品的分析方法，通过对比空白血清、含药血清的成分异同，确定大鼠口服生脉散后的血中移行成分，并利用质谱数据表征血中移行成分的结构。结果：大鼠口服生脉散后（12g·kg-1）在血中分析鉴定了18 个血中移行成分，其中5 个为新产生的代谢产物，13 个成分为生脉散的原型成分。结论：血中移行成分及代谢产物可能为生脉散的体内直接作用物质，对其进行深入的研究将有助于阐明生脉散的有效成分及作用机理。

Serum pharmacochemistry of Shengmai San (SMS) was carried out to reveal the bioactive components of SMS. Using the UPLC-HDMS technique, the chromatograms of SMS and the rat serum samples after oral administration of SMS were established and validated. To analyze and compare the chromatograms of rat serum samples obtained after orally taking SMS and those of the control rat serum samples, the constituents absorbed into blood were identified. 18 compounds were detected inform the rat serum after oral administration of SMS (12 g/kg). Among which 5 were new metabolites, and the other 13 were the prototype ingredients of SMS. The compounds absorbed into blood and their metabolites may be the effective constituents. The serum pharmacochemistry of Shengmai San needs further investigation so as to illuminate the pharmacology and bioactive mechanism of SMS.

科学技术部 “973”计划基础性工作专项 (2005CB523406)：基于体内直接作用物质变化规律的方剂配伍研究，负责人：王喜军；科学技术部重大新药创制专项（2009ZX09502－005）：中药复方药代动力学研究关键技术，负责人：王喜军。